VolitionRx Limited (VNRX) 15 Nov 222022 Q3 Earnings call transcript

Good morning, ladies and gentlemen. Thank you for standing by. Welcome to VolitionRx Limited's Third Quarter 2022 Earnings Conference Call. [Operator Instructions] This conference is being recorded today, November 15, 2022. I'd now like to turn the conference over to Scott Powell, Executive Vice President of Investor Relations. ahead. go Please

along and for operator financial to earnings upcoming of today's operating recent of Thank and activities Limited. welcome, This call key XXXX, quarter third VolitionRx for Volition's a call conference discussion results our you, milestones. the everyone, with will and cover

Officer and open Butera, Following our Mr. are call will call our Chief Officer; a Tom the of President Dr. Executive prepared Executive subsidiary; Officer. our Terig we question-and-answer Veterinary to Chief today Chief Cameron conference Hughes, remarks, and session. on Volition Reynolds, Also Mr. Financial

in on conference now to from quarterly most Commission. results President we over XX-K, used Before and remind implied cause Mr. made call Cameron? the are obligation operations update and or and by Litigation currently statements associated of recent call or XXXX. Cameron events, the have statements factors as will beliefs to Form upon Executive of future on these I'd of and of I'd the uncertainties annual risks, reflect XX-Q, to on during reports we Securities identified assumptions conference an statements may future on Reform factors significantly information Act like materially our a that forward-looking current Officer, Exchange this number provisions of begin, Chief actual based Securities to these under any the covered these views our events based our we do like to everyone that We based the concerning future results our as may Private achievements other undertake not be with statements our assumptions, include Reynolds. us. different with turn this statements, involve These well safe Because course forward-looking vary the have information actual performance to report call. discussed on statements results, expressed or available harbor Form some the various filings risk

thank earnings your joining And given call We everyone XXXX Scott. for always, earnings the as season. especially busy third Volition’s quarter time you today. Thanks call appreciate

commence will discuss of provide by financial great progress team Nu.Q have report. Nu.Q then a update on and will to the Volition licensing making rollout NETs, Officer of as update well And Tom been of Nu.Q with our call finally, Executive provide Chief Butera, I'll key our to to brief Terig on We the global the an another pillars, regards Vet Vet a Dr. supply with agreements, who as Cancer. the

without update across So been further what's Tom an to time ado, an our I'll you incredibly for hand exciting for team. vet on

show, the with ongoing I was payment of executed to Heska via new vet the we with Skill, agreement, Heska of in animal at a the England These this agreement at lab will available of agreements, I just in the test Test clients. also this detection were world. mutually Nu.Q move deal to the end, The this anticipated market, and Europe Thereby thrilled also to this Through subsequent soon which of over enough, of we $X.X signing York month, available awareness prompted the payment do which point show. within Nu.Q agreement. very mass of Heska’s Heska’s test interest with generating signing that together Heska’s million the million screening not agreement. cancer Cancer in to be future. the a will will and to working Cameron. of in the sale towards that for delighted the of final care schedule screening Test which and product market teams and with know in point care the on care. an order and receiving dogs techs in it's This much of will our of achievement has look point reference of be further absolutely we we is upon mission much, and provider And of anticipate and New veterinarians the Heska’s use publication solution breakthrough delighted laboratories. million work look Europe. care payment pet is a a interaction want worldwide we've week to nearby of means Heska launch aid and the product the morning to $XX through a in vet launch very Launching revenue Europe were I agreement, as veterinary forward the as care monitoring together labs. previously relating States, the pet any in forthcoming as to significant of London health. Test United veterinarians early in milestones, sale flagship million leading in the London, Last is This the the a the interest am show. our point market to Cancer is near with cancer folks strong commercial Veterinary Cancer the launch will that extensive Cooperation, quarter come great largest for are now articulate an broke to the good our And through global the a the due level. achievement indications near launches, for million US. $X.X Interestingly be global of the of and received reference likely lifetime the $XX Volition to care executed, to the Test can provide test diagnostics the But updates first laboratory Diagnostic the Vet team. the below. based at I'm owners means I product attending that launches news providing on agreement speaking a around of XXXX. in the first announce And transformative Nu.Q relating I we And upfront veterinarian recognized Vet by are health States payment enjoyed a of early Nu.Q half at network been now for United then lab supply advanced of the any that leader supply Vet booth also pet not the the announce you Cancer Volition This working reference thrilled and while a I'm XXXX just launch. towards cats the Heska’s important Pet this say morning, we our forward clinical one in will well. European affordable here Network so our across very launch of reference the officially most first with in milestones product, leading progress $X subsidiary. of receive the make attending. the via to of to in Thanks commercial and And both number market the product. as of accessible up company early of repeat US its midterm continued providers everybody. Vet XXXX. asked launch and launch world's their we

time every the deal reference greater these be And expect components long-term expects be market most make bring the where particular, In addition Heska to kit, market. and Volition the payments incredible in sale or of to than component. payment through the sale millions that these kits a significantly in for key ongoing for the supply potential, payments, test milestone revenue of relation will sold. will is of for that the that product money to a are of likely exclusive care and we with a to will point key this tests Heska sells for receive a Please lab market of the from remember, Volition

for hard running our for global, make year. other I And this of earlier, the team spoke either more global XX ongoing to outside analogy years I market or continue these fragmented, providers I licensees least is the This and expect revenue think company we outcome test, the fairly work use geeks, local the like throughout bring solid where of progress significant. one this will today. significant an Europe, Volition end when launching to anticipate where to think other particularly their you'll with at are we So And be we very the of that in and with of progress year. an company of distributors, one. excellent with our and the fellow Volition, I space about five, total before

Our ready. rocket is

achievement on thank go. for are tremendously systems taken It's there. and the a are rocket. belief has the company. their yes, us. We the to deliver we in now All investors time crawler And for launchpad, But we exciting our the rewarding long-term

And discussed high over an outcomes visit treatment the chance symptoms believes to quick the and And to per early incredible XX can least and approximately Nu.Q are millions cancer help allowing at provide and for those Volition But noting, pet screen upwards. under dogs dogs as at age, of have as Test one we animals XX% seven that's years and recap, of to detect million before. for there just care even stage, a of breeds from four of save remind the wellness improved worldwide. it's why veterinary lives a cancer plus those in before worth improve at annual opportunity have annum, Implementing appear, And an breeds outcomes. here are all and of better which risk Vet you, risk. people help States. senior commercial effective are years there We United opportunity dogs identified will just Cancer XX visits at will

dogs your And Vet on of before move that I updates, again the commercial innovation. update team. volition So R&D might for R&D on determination but dogs, monitoring also get not has just Thank and in for A&M, supplements cats thank tremendous the importantly, of use work only both to and It tool. XXX veterinary each ongoing screening Nu.Q work that highlight Vet and announced From with thank of and the specializing medical radiation have brief simply and company that's perspective, news this veterinary renowned to rocket we oncology. for This out excited and were whole yesterday, I study member this launchpad. clinic keep an just a hard perhaps referral in Volition at taken research commitment. a every the XX as from at and critical to looking you your supportive Texas most you Cats I'll study and a Oncovet, Nu.Q

our Director to list and Vet nucleosomes circulating This study Oncovet’s led be and Cancer monitoring of are is growing more adding Nu.Q excited We data cancer cats evaluate non by cat of interventional using dogs Dr. Benoit, Volition’s Jerome to being will research. Clinical with Test. and

the veterinary space, leading world's those is familiar For with President the the is you Dr. veterinary known of Benoit of Esvonc. the Veterinary currently oncologists European less Oncologist Society and of one of

of yet a key relationship in well very start the range product news on Terig? in clinical to are lot with with that, and meaningful far hopeful dogs across sharing simply design over I look we in is Test broaden forward is And working for for of to the that to an Vet Oncovet this And hope and Oncovet such launches We are Cancer we be year. long-term Nu.Q updates how Terig the and due early as cats. the in cancers to effective honored with will has known In the XXXX. So very veterinary not different are leader. Europe trials we again, with of detect can we get much this gone further species. of hand very happier seek And course. management the be commercialization opinion providing we summary, results it I'll could now so a report. financial

end ended now much, quarter results million equivalents provide very second I'll And quarter, of XX, XXXX. of today. We you summary the everyone approximately cash financial Tom. thank for $XX.X ended cash XXXX. the million, key September compared of end our and the Thanks at million joining $XX.X the with a quarter for the and with at $XX.X the earnings call of

underwritten fees through During public offering an common approximately net this $X.X in expenses of quarter, our we million stock. cash of received underwrites and

in program million US. portfolio $X.X further EU, the Volition’s a Nu.Q Belgium non-diluted across secured funding key at UK to we from an for capital access Additionally, invest sites product in risk fund the early more and

funding. of the As at down million we've drawn of this $X September, of end

sales Just for stock distribution aftermarket the we common third program. quarter, during equity the under of information made zero our

as revenue relevant manage in it in deferred not We the continue approximately our payments period received approximately is period operating standard. in and payment that $X.X carefully milestone year. March. of for the in $XX,XXX million was cash the been received receipt upfront excludes the as the with months It reported $XXX,XXX revenue is three figure averaging noting the of fully prior for same while in Heska worth recognized an expenditures Revenue for with activities accordance has revenue million $XX this net versus accounting This nonrefundable, to XXXX and in has from cash per used end year-to-date in Corporation the month of been September. accounted been has

recognized two payments paid million the relation mentioned expected with Tom the half following in anticipate milestones of lifetime was will achieved cat first be will Heska it the just XXXX the payments $X and due totaling Heska care not has to XXXX. of launched. most which revenue in of This the several be $XX during will early earlier, payments that point in next of clinical As the the million publication data likely use of final by We contract. milestone be over been yet of first product as

and resources to the Given sheet the launch expect in see worldwide our milestones. anticipated finance upcoming as the the balance confident the of revenue And start midterm, are we to we deliver expected short on in have XXXX. our ramp following best to to we current products to

We we short term our our we believe markets from previous with it and I'll addressable proprietary to discuss Vet calls, believe total very the helpful. the hand notably that can develop Nu.Q Nu.Q product discussed platform. significant, over Cameron should addressable the most to business range, back are future on As Cameron? be given NETs and we nucleosomics in market be further updates. now happy calls for in I'll

expected we discussions licensing development and to very we the sites trials. large research major conduct access significant DXOCRO sepsis scale units say during I'm terms. of portfolio our Food clinical objective Guy’s assessed The presented narrow progress US. Cancer. will six announce future will well those Biomarkers the Tom into very quarter and sequential webinar up setting claims can us clinical addition Sepsis wrap and Comparison Biomarkers three validation Namur, call two Nu.Q trials, subsequent This will allow Volition’s I'm number with in the findings FDA in with XXXX. Nu.Q score Nucleosomics and to Dr. in finding all been and COVID-XX delighted of Society Early starting program And Promise severity thanks are sites patients announce we made our of our US on I'm great sites a deepen United separate in and to critically the website. to currently distribution last in studies Sharon of to assessment My a the are or actors our severity Septic tests in a help investigate thank product States in centers and the technology in highlighted by the call, Test clearance, Nu.Q we well our with benefit breakthrough is with centers sepsis potential And patients half is we using to collaboration help key clinicians Subsequent the Terig. they've forum. highlight use infection today, and the the approval test with Nu.Q the the is submission year, the and the the NETs COVID-XX weeks. quarter, with coming functions progress are results on on across in application Cancer marketed and sponsored comprehensive in during assessed during that currently Patients anticipate NETosis organizations multiple Nu.Q of And our for Thrombosis the NETosis liver, We Thomas' incredibly quarter It Traps, initiated research Nu.Q clinical to our studies. Thanks, Great Observational speaking of determine have in XXXX up great GenomeWeb using happy program. organ SOFA researchers you, multisite Critical commercial disease. identified and NETosis, Evaluation project useful in progress SOFA from efforts and support cardiovascular, to partners, today NETS St Administration, this end, published updates. of visit conferences attendance the multiple the how Nu.Q something a at with We disease studies also attendance an pre and utility third develop entitled on And in the University GenomeWeb world's two presented The partners. failure will To MD Studies, spearheading and an device that Extracellular third US. the US. we XXXX. a blood with coagulation appointed on commercial with to measured of kidney, leading of our of International demonstrate brain, updates the July. other study These in studies of Anderson. market interest regulatory with I the to will Nucleosome other These in the onboard routine product leaders excellence score, the moreover, great system, watch Biomarkers to titled, We're two discussions in with Hospital anticipate pillars, at score. and the of and organ Drug of of forum. clinical Symposium delighted test, the in anticipated entitled indeed. team undertake to the DXOCRO Andrew further levels was authorization These a first and ill elevated quarter , is Neutrophil PolyBlood sepsis. results actively audience. to that cancer. the in happy London, lung, in Aswani on legal NETs we of to highly and team be This FDA just the as Inflammatory the recruited one Congress At second institutions Also Disease. international correlate paper The have Shock ISDH And studies and also as cancer to Hemostasis, of presented series to a intended International the and the underway. review University the Indeed, using in in and of engaged excellence clinical specific gain demand, data Ballesteros NETosis, that in with have fantastic of patients chosen a single a our poster down and by of get and presentation in the making first at directly and the third to a was with the opinion also the next Belgium, research with the number at a we attended many of correlated contractual indications NETs the test be working test in test network hope real were key patients.

at XX a is patients quarter, they also shockingly role Texas and critical the of are immune to the third cancer Traps, with it. of are evaluate underplay times patient sponsoring earlier announced and sepsis Cancer Neutrophil weakened patients Center risk treatment with University NETS in for the developing more of sepsis, if early sepsis. higher have a we and to die Extracellular outcomes. research have patients MD likelihood Therefore, As of Cancer it and develop cancer improve system, Anderson for quickly likely initiate physicians in

Anderson evaluates future. research we're week. Nu.Q this MD is lastly, using study right that potential news to cancer look in and with important the study on And management updates with And us forward collaborate NETs results and of Our risk further at the out up bring sharing utility date in last to patients sepsis. to and an the the of delighted

ILYAD evaluate when lung will Cancer is backed year. Nu.Q largest a with the alone, hospitals, wide-ranging million as Lung screening We early the have the that biomarker a We know of lung and and over blood ILYAD lung real detection X.X cancer common in the university participate performance France’s for there's most of with used globally. Initiation the HCL, in Screening, for lung prospective of cancer, CT each the deaths initiative next visibility in and of a early scan is the evaluate screening a Lung conjunction worldwide, program study the effectiveness for test of de government to a detection unmet cancer a been Hospices screening to Lyonnais second year. the the tragically invited of cancer Civils of The study need a biomarkers cases cause Lyon, is cancer performance lives of cancer screening. study Volition’s saves assessing with clinical

goal XX cessation campaign, been lung indeed, year, part screening one And opportunities. a one awareness next ultimate intervention at over and and cancer that screening pioneering developing the the HCL and take have encompassing first France expected of recognized subjects with program. report proud part need have of It's study on XXX subjects the to we're colleagues national be study I'm recruited. a delighted over will smoking already of ILYAD in their the Our the to

regulatory truly quarter we're global as progress strongly with milestone company And we available in excited publishing to in potential for both Nu.Q Cancer So to is exciting have in clear the company from with regarding fantastic for sale whole forward research our like I'd France. business GI and I results other position Nu.Q very Vet our sharing and along much this much payments, platform indeed, global pillar the and Healthcare months or and look five to revenue supply Vet joining the very made Lab, at the us excited our work hurdle, with players to happy is major we're news progress kits the another Nu.Q indeed key Singapore, program new to space of available, components and a the I our so staring coming during truly, lung heart an and but over is areas. market an study in by Test phase development business volition company EU It in in licensing fast-moving the call, And studies, as the our NETs rocket indeed market powered and in local Portugal, also of to Nu.Q has take soon years be key rest delighted After feel as and questions. the today. earnest. with for all and data, with the well agreements. commercialize discussions key exciting strong this an I purely positive crawler our also some healthcare at you key our our our publications close by achievement about of ongoing of and access announced. significant compelling we I'm the into extremely more an back here the stream further for launch Nu.Q. to screening pad. the pillars, of regulatory explained of of underway to absolutely many is the clinical the in many thank delivered the of and with Operator? clinical to get to revenue wide DNAtech Sage Volition And commenced be we're of cancer borders. journey. part work, recently next I'm milestones company to not epigenetics. cannot board program of in And a as healthcare for pet our and products. US, our government [inaudible] terms to in commercial I'm Texas hard generate leader ranging only and have the

Instructions] Michael first Okunewitch with comes question Our Group. [Operator from Maxim

Hey, my couple last you've like thank you of lot taking of guys, questions. And progress the a made over congratulations. months. for Seems

first to from that what it's positive? result guess and the commercial the product if I timelines CE data in differs in is using it in for this this particular And potentially I like So Asia? that bit done know from then part. study? Is I'd this a one get of more on the a your are ILYAD Mark the work how assays? study lung multi could And a you've

Yes, very question. good

lot. data which the there. from we've Asia, we've obviously, a very had issues other pandemic, been there's And good So obviously, about countries during in talked

a they to closely see keen the national if and very have close Program. Europe now good they're absolutely focus how we our home. to work. We're the to with seeing can the added our in So do. they working leaders tests very world National And they're and very running Screening And France. it's to trial They've in in university been what be

product, the of will currently could it FEMA few testing different depends the what part be they're a on it include final that is study. what assays, what is So but assays determined by

should and be problem, goes Screening year, they lung added is France. aim, if would by the the now end finished would they National be it less have no next to year. study in the They've Program. of got massive well the obviously everywhere And So underway as next a as cancer like

trying do really to something government's the about So it.

a how results we're or by field, it next to we'll great with we study, Absolutely end goes. top and what we've and round very to But of of Asia good the see really very part adding as it, in trial, seen in leaders be and as have we So encouraging. should first the it their have happy hopeful, have this finished worldwide they we opinion and do, we're year.

Oh, yes, that the this thank it Or they where reached something them you of saw potential a do? to to Oncovet, is you with the is out regarding for that. the you to then then out Nu.Q conduct And study to study? reached and program

Tom?

Hi, Michael.

in a that, reached he Just were well, outreach. staff interested Dr. as interested because so as flattered in and delighted actually very Benoit us and number add all has to there his very of our oncologists no we Board of to was platform, by we're out was his well, and

All you last that. for one. And right, one then thank

Sorry go ahead.

I fantastic. his Tom verify speak interest, of and from Is think indicative view. inbound has normal interest interest to the We're it people? that's you doing shows the vet to point inbound from level and lot of Tom, absolutely of been interest. this want a can do

the of initially which Medical Chief Yes, is just with at That's president similar us, American on he VCS also Veterinary actually this mean, Benoit contact Dr. Esvonc. Group, to the is Mike actually Oncology where comment European I Esvonc Robles who's the made our is he's President one Officer Dr. is Volition. last which of to Group,

the veterinary London, we Show, obviously, colleagues interest and speak, Netherlands, the as we and Vet a as side general as we spoke as are side, lot I'm that right the well spend invited am was Portugal being practitioner in even of my you conversations invited, on time invited from making, know, attending London to so in well continue Europe and lot now, Europe to of here everywhere in quite to going ones to both a oncology a speak [inaudible] we of is tremendous are continuing attend, going interest to personally we're week, in just and I domestically the So go, the being this to presentations the robust, we're to we be lot being there. the the to

invites and us this Germany to from So these personally, are frequently they summer as were coming reference France past to well. with as

is the attention So again, by we're delighted getting. and amount the flattered of test

the programs how vet unfolded. see It's you. Thank exciting certainly to

follow Just and last question, back I'll that the to one hop in queue. up then

a milestone Oncovet publication given million that milestone. suspecting is Heska cats from $X publication support a including could are you this that once the that from cats, that in get you For study,

as studies Yes, they're the align Xwith fact out we obviously, that the And research the we're additional support up we the studies well. that that and we'll get out we're KOLs additional doing. doing and the work, aligning also, reaching in to like to to we're to reaching that feline were running that see the information US. look And

our cat to the of at supporting value So again, lot a going obviously additional in tests our to validation credibility of is the parallel studies, test. the lend different locations of

GI other to need Heska. And partnerships it'll very the we to of in demand, the with large through generate it's fantastic of last with And potential or they'll strongly support expect other. generate company, labs, and be really big product launches the them. just term think amount going had to the never the short point get running we from are and Singapore, critical for Lab they each Texas, demand off. mass and in a I to but the But the take relatively We've in small

we're reference point in of And labs. care, and so lab, launching, think, we on

and from generating. it team big fantastic have So off Hopefully, expect in covered, been all we'll hope and two really companies we'll would once the meet taking to vet the early has start the which launched would be next they've to demand big particular, the that just supply year. companies,

dogs XX United touched even there. remember, the to cats. that's on close these opportunity million other thing to potential And XX States. one haven't we the in million And There's

for analytical we're So the well. be as is on studies us going immense the doing feline to obviously,

Bruce with Company. The Benchmark The from comes Jackson next question

up for to good A my the Nu.Q on and CT of study. Are questions questions. Hi, couple any follow thanks evaluating taking morning, addition in other test? testing modalities ILYAD they the and

lifestyle other and and there. we only Not was tests CT no, developed the areas what but from and and study aware, the then on blood blood that are test choices the I'm knowledge, scan was understanding, I my it but to and where it my but smoking only

very certainly could be a easily. Because can So something really blood know, run not I help. hopefully routine, part. to we mean, another test there and be you important isn't as They're

for. we're very it's So something hopeful

of end be screening XXXX. their of and in terms of what when review then national up might developing they intended And in finish terms period, in plan And happens Tell what plays out, this the enrollment terms how those so us is that of after guidelines. place. in

They're looking strategy. comprehensive very for a

because test too happens I as scanning, deadly think blood, where it incredibly between mitigating was they you lung know, program, cancer your smoking, can outlined Bruce, is mobile comprehensive and in a quickly. scan centers, release, very a little press and all CT the

we'll they're for comprehensive be we're gone looking after And trial of system out part of has a a what So they to through do. the this find hopeful program.

in DXOCRO back as liquid actively cancer the be the also the we've can be they're done of to And year. quickly. now, heartening the the end of data the human tumors. they're the Nu.Q Asia. in it. given They the good our decide now package other is, next the then lot And to cancers, see have we been it government looking which reasonably a And what fantastic we'd particularly in NETosis. of very base So Europe expect also that very government, very it's And cancers, be human has basis forget at is we behind I think and had space, we good so can now it'll And keen don't -- vet will to the in how platform be data the trial very resources by put running that them. very in have hopeful a works, been in helpful a London, that study the

and a many got the grow which said, pad, strongly to we soon. for companies we've launch demand Tom which got we we've lot rocket launch And once the going on expect So be vet liftoff. strongly expect the big now, are on. things as to the really to so And ready take the really market

Terig, turning time, is the sum payment the to the for milestones vet original Okay, space period be would going you. those of also certain upcoming a over amortized lump Heska be great. milestones or to payments And on question to over then being amortized, the are

lump as first we'll exactly cash, get will be but we they to as same sum use treated be them the which payment. as payments, the able So will

product from a be So the perspective. they'll amortized over revenue of life the

you've agreements just put then are to place, coming in going new And be with the revenue. how those that to you in

a we get time for So test. agreement, the a sell new payment will every they

time company similarly the a test. new test, will payment a Heska a Similarly, will paid. Heska we sells sells So where this every way to sells get every time Heska, test, we a time every get that

labs do reference we're thing see, One a and care. Bruce, they what Heska, can you clear to the got of a to make here, there of as we're get and of all labs, many reasonable we'd companies really possible. Because a revenue large, the very percentage we the bunch we expect as more, do. deals to looking want in But we've fantastic the reference got looking as bunch exclusive a very out the product in selling partner, point of

Because that in products. but biggest for in labs. to most our reference The We Tom space alone. said, we companies of them market large there's know of point us as our the target out millions do have pushing with upfront payments thing out dogs. XXs large expect not get we the important US nonexclusive So the the in coverage with is

we're get each a the as test much want similar for structure many run having per as we on platforms as we one to get paid to vet every So how the opportunity test. in looking possible. And possible

potential, So that if to they're expect very them reach they reach. ourselves, particularly lucrative we for

comes with Steven Zacks. The next from Ralston question

If to second the of those during said had Discover. discover, on fourth schedule? this multiple to up Are it $XXX,XXX of -- and aggregate a be were we they talk on had about could also There half annual tended lumpy? you Nu.Q contract that -- You year. an worth sign a was ramp expected quarter

be in is now inbound Yes, all, we Discover lumpy going but so rightly them out, And term demand the up. last as And getting as we're them very, uses, bunch this different early to it many so had being our are fantastic year, very all lumpy companies, outbound of of we've different a on and all pointed we to by trials does now well, front end ways see making platform it cricketing you the foot. will and so a different year. use we're used get interest closed interests

see to next a expect we'd bunch year. again more So

range out. through and really Because now of been well, different the some we've now taken we foot space, think Discover we've we well, the very in follow members get already new And on to line the so potentially actually contracts next well, year, a we've So companies ones in come that and very and as it's wide more active of It team are are found. more. expect lumpy, on a perhaps is well to hundreds to progressing is, as there, expecting range with there a clients on out will very signed, the the of really Nu.Q up lot who areas. bottom gone us front help very the get we've work is

you. Thank

there few areas. R&D noticed, in quarters certain your at that aggregate in of G&A Is that? the But model is target. actually up. quite changing. mix employee are on going are last And any and R&D expenses the down my Over it's are the G&A number to the I've the expenses in XX-Q, you've expenses, and I least employees added going mean, a significance

Terig?

we keep building So much out they infrastructure is have under do the for future are G&A, with where try very business. we the yes, and the G&A, control, added

element. So the support

terms R&D, and think, In staffing got number, within which got, out. been of up that I we've lab, we've the we've innovation building

building elements things we've think the also out. you've of of that see the I also within there. which one that's R&D, you'd production been got the And So side

to basically it's year. get in the support we the the expect to coming infrastructure So business building that

right, you. thank All

expect at to front Terig capacity, sure, Steven, And the the make to said, we as as through the so strong administration as next careful to company, as we new to costs a really low possible. we've production demand been really be rising mind, keep very really of meet the can our year. to speak, people hire

the development teams So well products. we our marketing the the products as And want able of to of meet as that. be supply to the the for in also

also So edge to on products we're on tell, trying and very, to -- you carefully we can cutting current want the our we -- of focused now, have as we're very stay epigenetics.

done capture nucleo some the and work. other we've through So research side

an our with we're is to a awful of same And the not things platform the truly platform. very the doing much careful do managing We're adaptability how of doing given So we all lot are. exactly remarkable. with we're spend,

a we I So a unique proposition. very of lot think ways have

provide Taiwan? you marking could question, last on by University my an of And those National conducted you. being update the Thank studies

been been come and China, of we some has we've in a we've forth they a quite work Yes, so bit. Taiwan back and through. provide more will as updates Asia. lot there issues in And with done them Obviously,

future them done in colorectal lot in like we will and and update. a to have once with of what Justin updates those the work lung. looks And for be the finished we

more been information up see, very from there. end come more fully starting you of but lock As follows up lung had why after update of That's to now open with we just downs back the we've happy pandemic. well. been but very the to is will partnerships particularly the work it's of it's we the very can we've Europe. have the going when And And very, perhaps we've down getting some Asia, in hopeful, the conferences,

done during these So hopefully by lockdown the the picking in a that pandemic. to times keeping to be lot all our has team will going different job in very Jasmine difficult up a spearheaded due But great areas.

questions [Operator Instructions] closing at to floor back There Cameron this Reynolds comments. further over ahead, no sir. like go would for are time. I Please the to turn

really it's vet going all space make strong studies you cancer very think a the products very would increasing the as progress in very be we're US including yet human amount range launches exciting, call more generate and side, getting revenue. in and some and it's I very more progressed launch we next Thank hopefully few months the soon, of our NETosis some, which for exciting help the all and of again on and getting big joining to a

be So exciting to a time. it's very going

to look Thank in for your forward coming keep contact, I you the please soon. So time. and updates

conference today's This concludes call.

participation. for you may You time. day. this at disconnect Thank lines your great And your have a